Answers are grounded in this paper and cite their sources.
Economic evaluation finds that the adjuvanted recombinant zoster vaccine prevents complications in older adults, suggesting its use in public health.
RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.
No takes yet. Share an insight, caveat, or question.
Zarkadoulas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: